Back to Search
GEOLANI DY, M.D.
M.D.
Urology Physician
NPI: 1710243951IndividualAccepts Medicare
Specialties, Licenses & Credentials
Urology PhysicianPrimary
Urology
Code: 208800000X
MD193211(OR)293674(NY)
CMS Specialties
PrimaryUROLOGY
Education
OTHER
Class of 2012
Research & Publications (20)
Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144.
PMID 19423501·Clin Colorectal Cancer·2009
8-other
Emerging therapeutic targets in non-small cell lung cancer.
PMID 19349491·Proc Am Thorac Soc·2009
6-review
Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results).
PMID 19632379·Ann Thorac Surg·2009
3-trial
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
PMID 18676837·Cancer Res·2008
8-other
Identification and characterization of genetic variation in the folylpolyglutamate synthase gene.
PMID 17875718·Cancer Res·2007
8-other
A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
PMID 17803883·Mayo Clin Proc·2007
6-review
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
PMID 17687151·J Clin Oncol·2007
4-observational
A multidisciplinary approach to the management of breast cancer, part 1: prevention and diagnosis.
PMID 17673070·Mayo Clin Proc·2007
6-review
Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.
PMID 17409859·J Thorac Oncol·2006
3-trial
Angiogenesis inhibitors in lung cancer: a promise fulfilled.
PMID 16764755·Clin Lung Cancer·2006
6-review
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
PMID 15867242·Clin Cancer Res·2005
3-trial
Obstacles and opportunities in the clinical development of targeted therapeutics.
PMID 16265875·Prog Drug Res·2005
6-review
A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
PMID 16087693·Ann Oncol·2005
3-trial
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
PMID 15999272·Cancer Chemother Pharmacol·2005
3-trial
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
PMID 15756013·Clin Cancer Res·2005
3-trial
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
PMID 15754203·Cancer Chemother Pharmacol·2005
3-trial
Complementary and alternative medicine use by patients enrolled onto phase I clinical trials.
PMID 15570083·J Clin Oncol·2004
4-observational
Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage.
PMID 15501963·Clin Cancer Res·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 222 E 41ST ST
NEW YORK, NY 10017 - Phone
- (646) 825-6300
Quick Facts
- NPI
- 1710243951
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 14
- Publications
- 20
Are you this provider?
Claim Your Profile